Aiforia collects 6.4 MEUR in a directed share issue
Summary
- Aiforia successfully raised approximately 6.4 MEUR through a directed share issue, with new shares subscribed at the closing price, indicating strong investor confidence.
- The share issue involved 3.6 million new shares, diluting the company's share capital by about 9.6%, and was executed without a subscription markdown.
- The recent funding, along with a preliminary agreement for a 20 MEUR loan from the European Investment Bank, strengthens Aiforia's balance sheet and supports its growth strategy.
- The analyst views the funding as a positive step towards operational stability and profitability, minimizing dilution while securing long-term financial support.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish 06/26/2026 at 07:00 am EEST
Aiforia announced on Thursday that it had raised gross proceeds of approximately 6.4 MEUR through a directed share issue. We consider the execution of the issue excellent for the company and its current owners, as the new shares were subscribed directly at Thursday's closing price without the markdown typical for directed issues. We feel that together with the recently announced EIB loan arrangement, the issue removes the company's financing risks for the coming years. The funding round is in line with our expectations, and we will update the issue details in our model in connection with the next company update.
The issue was carried out without a subscription markdown
The share issue involved the issuance of 3.6 million new shares, which dilutes the company's share capital by approximately 9.6% The subscription price was EUR 1.772, which was exactly Aiforia's closing share price on Thursday. We consider a zero markdown to be a sign of investor confidence in the company's growth story. We had previously estimated that the company would raise 8.0 MEUR in funding this year at a share price of EUR 1.60, so the terms of the issue are largely in line with our estimates.
The financing puzzle falls into place on the path to profitability
We have previously estimated that Aiforia's cash would be sufficient until the Q3/Q4 turn of this year and that the company would need around 20 MEUR in funding to achieve cash flow positivity. Just over a week ago, the company announced it had preliminarily agreed with the European Investment Bank (EIB) on venture debt financing of a maximum of 20 MEUR. The 6.4 MEUR equity financing now raised immediately strengthens the balance sheet and liquidity, while the EIB loan arrangement, once realized, will provide long-term support for the implementation of the growth strategy. We see the combination of these two instruments as a good solution for current shareholders, as it minimizes share dilution at current valuation multiples while securing the company's operational stability for several years to come. The issue now arranged may also be related to fulfilling loan conditions, which cannot be concluded with certainty based on the releases. We recently commented on the planned debt arrangement here.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures08/03
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | 24.0 % | 45.0 % | 55.0 % |
| EBIT (adj.) | -11.2 | -9.2 | -8.3 |
| EBIT-% (adj.) | -316.3 % | -178.7 % | -104.7 % |
| EPS (adj.) | -0.38 | -0.25 | -0.19 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
